COVID-19 Impacts: Hematopoietic Stem Cells Transplantation (HSCT) Market will Accelerate at a CAGR of Almost 6% Through 2020-2024 | Demand for…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the hematopoietic stem cells transplantation (HSCT) market and it is poised to grow by USD 4.64 billion during 2020-2024, progressing at a CAGR of 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AllCells Corp., bluebird bio Inc., FUJIFILM Holdings Corp., Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck & Co. Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and ThermoGenesis Holdings Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Demand for personalized medicine has been instrumental in driving the growth of the market.

Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024: Segmentation

Hematopoietic Stem Cells Transplantation (HSCT) Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41656

Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our hematopoietic stem cells transplantation (HSCT) market report covers the following areas:

This study identifies the availability of technologically advanced equipment as one of the prime reasons driving the hematopoietic stem cells transplantation (HSCT) market growth during the next few years.

Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the hematopoietic stem cells transplantation (HSCT) market, including some of the vendors such as AllCells Corp., bluebird bio Inc., FUJIFILM Holdings Corp., Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck & Co. Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and ThermoGenesis Holdings Inc. Backed with competitive intelligence and benchmarking, our research reports on the hematopoietic stem cells transplantation (HSCT) market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Visit link:
COVID-19 Impacts: Hematopoietic Stem Cells Transplantation (HSCT) Market will Accelerate at a CAGR of Almost 6% Through 2020-2024 | Demand for...

Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Its Clinical and Scientific Advisory Boards -…

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the appointment of leading experts in retinal disease, gene therapy and the complement system to its Clinical and Scientific Advisory Boards. The newly appointed boards will help guide the development of the company's lead investigational gene therapy, GT005, a one-time therapy being developed to potentially slow the progression of dry age-related macular degeneration (AMD), as well as novel gene therapy delivery systems and additional pipeline candidates.

This is an exciting time for Gyroscope and we are honoured to have a group of highly esteemed leaders in retinal surgery, ophthalmology and gene therapy join our Clinical Advisory Board, said Nadia Waheed, M.D., Chief Medical Officer of Gyroscope. We look forward to working with these leaders as we advance the clinical development of GT005 and our proprietary delivery system, with the ultimate goal of helping preserve the sight of millions of people who suffer from vision loss as a result of dry AMD.

We have embarked upon an ambitious journey exploring the potential of gene therapy beyond rare disease and building a pipeline of potential medicines for one of the worlds leading causes of blindness, said Jane Hughes, Ph.D., Chief Scientific Officer of Gyroscope. We are excited to welcome our Scientific Advisory Board members to Gyroscope and to benefit from the insights of some of the worlds leading experts as we advance our understanding of the role of the complement system in retinal diseases.

Members of the Gyroscope Therapeutics Clinical Advisory Board include:

Professor Jacque Duncan, M.D. Professor of Ophthalmology at the University of California, San Francisco School of Medicine.

Jeffrey Heier, M.D. Co-President and Medical Director, Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston.

Professor Allen Ho, M.D. Professor of Ophthalmology at Sidney Kimmel Medical College of Thomas Jefferson University, and Attending Surgeon and Director of Retina Research at Wills Eye Hospital in Philadelphia.

Professor Nancy Holekamp, M.D. Director of Retina Services at Pepose Vision Institute and Professor of Clinical Ophthalmology at the Washington University School of Medicine in St. Louis.

Arshad Khanani, M.D., M.A. Managing Partner, Director of Clinical Research and Director of Fellowship at Sierra Eye Associates, and Clinical Associate Professor at the University of Nevada, Reno School of Medicine.

Professor Robert MacLaren Professor of Ophthalmology at the University of Oxford in the United Kingdom, Consultant Ophthalmologist at the Oxford Eye Hospital, Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology, Honorary Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital, and an NIHR Senior Investigator. Professor MacLaren is also a member of the Scientific Advisory Board.

Professor Sir Keith Peters, M.D. Senior Consultant to The Francis Crick Institute in London and Regius Professor of Physic Emeritus at the University of Cambridge in the United Kingdom. Professor Peters is also a member of the Scientific Advisory Board.

Professor Hendrik Scholl, M.D. Founder and Director of the Institute of Molecular and Clinical Ophthalmology Basel in Switzerland, and Professor and Chairman of the Department of Ophthalmology at the University of Basel.

Professor David Steel, M.D., MBBS, FRCOphth Consultant Ophthalmologist at Sunderland Eye Infirmary in the United Kingdom and Honorary Professor of Retinal Surgery at Newcastle University in Newcastle upon Tyne, United Kingdom. Professor Steel is also a member of the Scientific Advisory Board.

Professor Bernhard Weber, Ph.D. Head of Institute of Human Genetics, Head of Institute of Clinical Human Genetics, and Director of the Diagnostics Unit for DNA Testing and Vice President of Research of the University of Regensburg, Germany.

Charles Wykoff, M.D., Ph.D. Director of Research at Retina Consultants of Houston, Deputy Chair for Ophthalmology at Blanton Eye Institute, and Clinical Associate Professor of Ophthalmology Weill Cornell Medical College at Houston Methodist Hospital.

Members of the Gyroscope Scientific Advisory Board include:

Professor Alberto Auricchio, M.D. Professor of Medical Genetics at the Department of Advanced Biomedicine, Federico II University in Naples, and Coordinator of the Molecular Therapy Program at Telethon Institute of Genetics and Medicine (TIGEM) in Pozzuoli (NA), in Italy.

Professor Pete Coffey, DPhil Theme Lead of Development, Ageing and Disease at University College Londons Institute of Ophthalmology and the Co-Executive Director of Translation at the University of California Santa Barbaras Center for Stem Cell Biology and Engineering.

Professor Claire Harris Professor of Molecular Immunology at Newcastle University.

Professor David Kavanagh, Ph.D., FRCP Professor of Complement Therapeutics at the National Renal Complement Therapeutics Centre (NRCTC), Newcastle University.

Professor Sir Peter Lachmann, FRS, FMEDSCI Emeritus Sheila Joan Smith Professor of Immunology, University of Cambridge.

Professor Robert MacLaren Professor MacLaren is also a member of the Clinical Advisory Board.

Professor Sir Keith Peters, M.D. Professor Peters is also a member of the Clinical Advisory Board.

Professor Matthew Pickering, Ph.D., M.B., B.S. Professor of Rheumatology, Imperial College London Honorary Consultant Rheumatologist, Imperial College Healthcare NHS Trust, and Wellcome Trust Senior Fellow in Clinical Science.

Professor David Steel, M.D., MBBS, FRCOphth Professor Steel is also a member of the Clinical Advisory Board.

Professor Timothy Stout, M.D. Sid W. Richardson Professor and Margarett Root Brown Chair of the Department of Ophthalmology, and Director of the Cullen Eye Institute at Baylor College of Medicine in Houston.

Full biographies for members of the Gyroscope Advisory Boards are available at http://www.gyroscopetx.com.

About Gyroscope Therapeutics: Vision for Life

Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing and delivering gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (AMD). Currently, there are no approved treatments for dry AMD.

Our investigational gene therapy, GT005, is designed to restore balance to a part of our immune system called the complement system. An overactive complement system leads to inflammation that damages healthy eye tissues. Our ultimate goal is to slow the progression of dry AMD. Patients in our Phase I/II clinical trial, known as the FOCUS study, receive a single dose of GT005 through an injection under their retina.

Syncona Ltd, our lead investor, helped us create the only retinal gene therapy company to combine discovery, research, drug development, a manufacturing platform, and surgical delivery capabilities. Headquartered in London with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness. For more information, visit http://www.gyroscopetx.com and follow us on Twitter (@GyroscopeTx) and on LinkedIn.

See the article here:
Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Its Clinical and Scientific Advisory Boards -...

How can nanomedicine be applied to cannabis? – Leafly

Imagine a world in which a tiny nanorobot could deliver a specific cannabinoid directly to your endocannabinoid (ECS) receptors. The nanorobot would be thousands of times smaller than the breadth of a human hair and could carry its small cargo inside a single droplet of liquid to deliver it directly to a target cell such as a cancer cell.

Sound far-fetched? It may be closer than you think, because researchers are making great strides in the fascinating field of nanomedicine.

The cannabis plant contains an amazing group of cannabinoids, terpenes, and flavonoids, and scientists are only beginning to unlock the complex pharmacology and potential of these compounds. Combined with nanomedicine, cannabis has even more potential to treat disease and provide overall health benefits for people.

Related

Scientists can manipulate substances on an atomic scale, in the range of 1-100 nanometers, or one thousand times thinner than a sheet of paper. According to the US Nanotechnology Initiative, substances on the nanoscale have very different properties than bulk substances dounique properties like better electrical conductance, higher strength, and different magnetic properties, light reflection, or chemical reactivity. Nanotechnology can be performed on solids, liquids, or gases to unlock these unique phenomena.

For these reason, nanotechnology applications in medicine offer exciting promise and possibilities, especially when applied to cannabis compounds. Many nanotechnology applications are already in usecomputer circuits made from carbon nanotubes allow for far greater computing power, and nanoparticles are already being used in pharmaceuticals to improve absorption.

Researchers work on all kinds of aspects of nanotechnology, such as finding the best substance for nanoparticles, the best shape for a nanoparticle for a specific delivery, and the best transfer mechanisms for specific drugs. Nanoparticles can generate heat, deliver stem cells, be radioactive or metallic, and so much more.

While many applications are still only imagined by scientists, at its full potential, nanotechnology could be the next medical revolution, vastly changing how diseases are detected and treated.

One of the best applications of nanomedicine is in the area of drug delivery, whereby nanoparticles deliver substances directly to specific cells, like diseased cancer cells. Researchers can engineer nanoparticles to be attracted to a diseased cell and limit the ability to bind with and therefore damage healthy cells.

Scientists at MIT and other institutions have successfully used specific nanoparticles to deliver drugs to tumors. Even more interesting is that nanoparticles are developed to work togetherwhile one locates a tumor, another can use the signal from the first to effectively carry the drug to its intended target.

In one interesting application, scientists have created a nanoparticle that looks for hydrogen peroxide present in inflamed tissue, then it releases a drug in that environment to target heart disease.

Related

There is great promise that nanotechnology and cannabinoids can make an impact on diseases like cancer, multiple sclerosis, Parkinsons, diabetes, and a wide range of serious inflammatory diseases.

Nanotechnology can help identify a disease at an early stage, perhaps even when a single cell has gone awry, and then deliver a targeted cannabinoid to correct a cells behavior, thus stopping the disease in its tracks. It may even be possible for a nanorobot to target a specific endocannabinoid receptor to shut down the entire inflammatory process for the betterment of a patient.

Cannabinoid nanodelivery systems have entered the research mainstream, with scientists working on biologically engineered cannabinoids and other nanoparticles to be transported to cells, and by creating nanocarrier transport substances out of metallics or other substances.

Delivery system research also touches on improving bioavailabilitythe rate at which the active substance of a drug enters the bloodstreamas well as improving the physical stability of nanoparticles and optimizing routes of administration, including injection, pills, or sublingual drops.

A nanotechnology-based targeted drug delivery system can be formulated to deliver cannabinoids directly to endocannabinoid receptors, where the magic happens. Cannabinoids can be packed inside a nanoparticle and carried to its intended target without degradation and with a controlled release.

Related

For example, nanoemulsions are already used in the food industry to deliver probiotics or other bioactive ingredients in a very controlled release. These nanoemulsions use a combination of two liquids that dont normally combinesuch as oil and waterto serve as a barrier to chemical degradation for the cannabinoid while on its journey through the body.

Other encapsulation methods can help with potency issues by increasing absorption, they can help decrease side effects, and they can help cover a substances bitter taste.

Specific cannabis strains could even have tailored therapeutic profiles, and cannabinoids could be bioengineered to produce enhanced effects.

Scientists envision a superclass of cannabinoid nanocarriers that have potential to treat a wide array of endocannabinoid insufficiency issues and thus a wide variety of diseases.

In one example, researchers are looking at novel ways to deliver substances across the difficult blood-brain barrier. This barrier is the bodys built-in defense mechanism to protect the brain, so the ability to transport substances across it directly affects a treatments efficacy.

To this end, scientists are engineering lipid nanocapsules decorated with minute cannabinoids like CBD as novel therapies for diseases of the central nervous system.

Related

Nanotechnology has already transformed drug delivery in profound ways, and cannabinoid delivery is part of this exciting future. There are challenges, of course. Cannabinoids quickly degrade in water and are susceptible to other kinds of degradation, and that presents delivery issues.

More recent discoveries, including the decoding of the cannabis genome, discovery of the main CB1R and CB2R receptors within the human endocannabinoid system (ECS), and discovery of other receptors, are also foundational efforts that contribute to cannabinoid nanotechnology.

The latest research shows great progress in the formulation of targeted cannabinoid-nanocarrier delivery systems, and as such may provide key therapies particularly for central nervous system disorders. As scientists continue to make improvements in both bio-efficacy and bioavailability, cannabis nanotechnology represents an exciting and brave new world.

Read more:
How can nanomedicine be applied to cannabis? - Leafly

Annual Luau and Legends of Surfing Invitational to make virtual waves – For the first time ever surfers scientists physicians and survivors will come…

On. Aug. 19, Dane Perlee rides a wave during the Luau & Legends of Surfing Invitational. PHOTOSBYJOHNCOCOZZA

For the first time ever, surfers, scientists, physicians and survivors will come together virtually to support the fight against cancer at the annualLuau and Legends of Surfing Invitationalon Aug. 9.

As UC San Diego events are being canceled or postponed because of the coronavirus pandemic, the annual fundraiser has transitioned to a virtual format to allow participants to support the fight against cancer from home.

Instead of surfing the ocean, participants are invited to surf the wave of cancer research as theyCrowdsurf for a Cure, helping raise money for research, education and clinical care. All proceeds from the 27th annual Luau and Legends of Surfing Invitational will benefit Moores Cancer Center at UC San Diego Health and contribute to the Campaign for UC San Diego.

As we celebrate the 27th Luau and Legends of Surfing Invitational, it is inspiring to see the local community continue to support the breakthrough discoveries and life-saving treatment developed by Moores Cancer Center, said Dr. Scott M. Lippman, director of Moores Cancer Center at UC San Diego Health. While we cannot join together in person for this years event, cancer does not stop during the COVID-19 pandemic and neither does our commitment to finding new cures and treatments for this life-threatening disease. Thanks to the generous donations raised through the Luau, we can continue to provide our patients with the latest individualized treatment and excellence in patient care that is only available at an academic medical center like ours.

The beloved fundraiserwhich has traded tuxedos for wet suits and ballrooms for beach views since its founding in 1993has brought in nearly $10 million for research and helped thousands of cancer patients through clinical trials, new treatments and delivering discoveries. Now, amid nationwide pandemic-related disruptions to the health sector, support towards ending this devastating disease continues to be critical.

For myelofibrosis patient and advocate Sandra Dillon, this support made all the difference in her journey with cancer. When doctors discovered a small lump behind Dillons ribcage in 2004which turned out to be an enlarged spleen, a symptom of myelofibrosisit came completely out of the blue. As a healthy 28-year-old, the last thing she expected was to be diagnosed with an extremely rare cancer with no real treatment options and a median survival rate of five to seven years.

What I thought was my whole life ahead of me was now just a few years, said Dillon, whose doctors tried to manage her symptoms as she slowly got sicker from the disease. I had such a hard time with my diagnosis and my experience. Knowing that there was no treatment that could stop myelofibrosis, I just didn't want to see doctors, be in a hospital or take any more tests. I kind of gave up on medicine in general and figured, Well, Ill just take the time that I've got left and that's all I've got.

Several years later, the trajectory of Dillons life changed completely when she moved to San Diego and was introduced to the team at Moores Cancer Center. Ridden with fear and hesitancy, she made the courageous decision to continue to fight for her life with support from her friends and husband, Casey Turk.

What I found at Moores Cancer Center was the exact opposite of what I was expecting. I was greeted with so much compassion and care at every level, said Dillon, who came to the center in 2011. Initially, I was afraid of being a pin cushion and just a number passing through a system. Instead, I found a home. Moores Cancer Center is a shining light of what treatment and health care can, and should, look like.

At Moores Cancer Center, Dillon met physician-scientistDr. Catriona Jamieson, Deputy Director of Moores, who enrolled her in a clinical trial for a new drug called fedratinib designed to block cancer cell proliferation. The results were amazingin a few months, Dillon was revitalized with newfound energy, less pain and a whole new life.

However, when the promising cancer drug was discarded for safety concerns and its trial pulled, Jamieson and her team were forced to turn to alternate trials and treatments to halt Dillons disease. With the health of multiple patients depleting in the absence of fedratinib, Jamieson worked tirelessly alongside scientist, biotech executive and Moores Cancer Center Board Vice Chair John Hood, who has a doctorate in medical physiology and led early research on the drug, to fight to bring it back. When fedratinib was finally approved by the FDA in 2019, it was the first new therapy approved for myelofibrosis in nearly a decade. It is now available under the brand name Inrebic.

Now that I am on the drug, I havent had to have a blood transfusion in over a year. I feel incredible again, said Dillon. What Dr. Jamieson and Hood have accomplished is incredibleits a blessing for me and an amazing testament to what is possible.

During the online fundraiser on Aug. 9, Jamieson and Hood will both be recognized with the Rell Sunn Award, which honors the memory of Rell Kapoliokaehukai Sunn, known as the First Lady of Surfing. Sunn was diagnosed with breast cancer at the age of 32, but rather than submitting to the disease, she lived life to the fullest until passing 15 years later in 1998. The Rell Sunn Award recognizes individuals who have made a difference in the battle against cancer and who embody the Aloha spirit.

This event has had a sustainably positive impact on our relentless drive to deliver new discoveries to the clinic with alacrity, and our unique capacity at Moores Cancer Center to develop personalized cancer stem cell, immunotherapy, and precision-medicine-guided targeted therapies for hopeful patients across economic strata, said Jamieson. To receive this award is such an extraordinary privilege considering that it honors Rell Sunn, a champion Hawaiian surfer who battled breast cancer and was the personification of hope, joy and the spirit of ganbatte, which is the Japanese word for never, ever, ever, give up.

Being honored based on a person like Sunn, by your peers and neighbors, is incredible. I feel very grateful for it, said Hood. I hope what we didfacing down the FDA with a small group in the company and doing everything we can to get it to the patientswould make her proud.

The virtual luau festivities kick off online on Aug. 9 at 5 p.m. Guests can expect to enjoy a program featuring: an address from Chancellor Pradeep K. Khosla, Vice Chancellor for Health Sciences Dr. David Brenner and CEO of UC San Diego Health Patty Maysent, messages from surf legends, Moores Cancer Center leaders, Polynesian dancers, live music and more. Attendees in the local region can also join in by pre-ordering aDinner and Drinks packagea catered meal and cocktails with options to be picked up or delivered to their home to enjoy during the event. Featured artwork will be presented by Southern California surfer Andy Davis.

The Luau and Legends of Surfing Invitationals Crowdsurf for a Cure is free to register and to attend. Event sponsors include: Cooley LLP; Lina and Christian Waage; Lisa and Mike Rhodes; Valerie Ewell Armstrong and Sam Armstrong; BioMed Realty; ASML; Arey Jones; The Allergan Foundation; and Pfizer. For more information about sponsorship opportunities and event activities,visit the Luau and Legends of Surfing Invitational website. You can also get read more about theMoores Cancer Center at UC San Diego Health.

Gifts made through the 27th annual Luau and Legends of Surfing Invitationals Crowdsurf for a Cure also contribute to the Campaign for UC San Diegoa university-wide comprehensive fundraising effort concluding in 2022. Alongside UC San Diegos philanthropic partners, the university is continuing its nontraditional path toward revolutionary ideas, unexpected answers, lifesaving discoveries and planet-changing impact. For more information,visit campaign.ucsd.edu.

More here:
Annual Luau and Legends of Surfing Invitational to make virtual waves - For the first time ever surfers scientists physicians and survivors will come...

Automated Cell Culture Systems Market to Record Strong Growth due to High Demand for Advanced Treatment of Chronic Conditions, Future Market Insights…

Dubai, U.A.E, Aug. 3, 2020 /PRNewswire/ -- According to Future Market Insights, the automated cell culture systems marketwill exhibit a strong CAGR of 8% from 2020-2030.

Escalating incidences of chronic ailments have spurred greater research in cytology and cell biology for developing advanced diagnosis and treatment. This is largely an end-product of boundaries in conventional pharmaceuticals. Furthermore, growing complexities of the nature of chronic diseases is prompting various technological advancements with regard to treatment, thereby bolstering the scope of automated cell culture systems.

Greater penetration of 3D-cell cultures have significantly boosted the adoption of automated culture systems, as is the need for faster testing of biological or biochemical activities. Furthermore, requirement of cell lines to devise vaccines for COVID-19 shall catapult the automated cell culture market in the upcoming forecast period.

"Key players are developing specific and specialty growth media with the aid of various technological advancements, which is expected to sustain market growth over the following decade," infers an FMI analyst.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-7860

Key Takeaways from FMI's Automated Cell Structure Systems Report

Automated Cell Culture Systems Market- Key Trends

Automated Cell Culture Systems Market- Region-wise Analysis

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-7860

Automated Cell Culture Systems Market- Competitive Landscape

Prominent players are concentrating on offering new products, innovations and collaborations with other companies to widen their outreach across major geographical areas.

For instance, in July 2020, Sphere Fluidics announced a partnership with the Heriot-Watt University in Edinburgh for developing next generation droplet generator instrumentation. This agreement is for expanding its advanced biologics discovery and therapeutic cell line development.

Also, in February 2020, Selexis announced the application of Bioprocessing 4.0 by incorporating automated systems such as the ambr and Beacon optofluidic platforms for enhanced cell line development.

Request special price for this Report to our Sales [emailprotected]https://www.futuremarketinsights.com/request-special-price/rep-gb-7860

Automated Cell Culture Systems Market Taxonomy

Product Type

Cell Culture Type

Application

End User

Region/Country

Request the Coronavirus Impact Analysis across Industries and [emailprotected]https://www.futuremarketinsights.com/covid19/rep-gb-7860

More Insights on the Automated Cell Culture Systems Market

The study provides compelling insights on automated cell culture systems market on basis of product type (automated cell culture storage equipment, automated cell culture vessels, bioreactors and consumables), cell culture type (finite cell line cultures, infinite cell line cultures), application (drug development, stem cell research, regenerative medicine and cancer research) and end user (biotech companies, research organizations, academic institutes), and across seven major regions.

Explore Extensive Insights on FMI's Healthcare, Pharmaceuticals and Medical Devices Landscape

Fertility and Pregnancy Rapid Test Kits Market: Investigate a detailed bird's-eye view of FMI's fertility and pregnancy rapid test kits market by perusing the report for the upcoming decade's forecast period, bringing to the fore valuable insights responsible for shaping the growth trajectory during the forecast.

Home Healthcare Market: A surging geriatric population pool is leading to an increase in the prevalence of chronic disorders, ultimately boosting the need for home healthcare products in recent years, concludes FMI on its report on the home healthcare market for the 2020-2030 assessment period.

Gene Synthesis Market: The gene synthesis market study published by FMI incorporates a global industry analysis from 2014-2018 and opportunity assessment from 2019-2029, delivering a comprehensive outlook on prominent growth dynamics.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries.FMIisheadquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latestmarket research reportsandindustry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

ContactMr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: [emailprotected] For Media Enquiries: [emailprotected]Report: https://www.futuremarketinsights.com/reports/automated-cell-culture-systems-market Press Release Source:https://www.futuremarketinsights.com/press-release/automated-cell-culture-systems-market

SOURCE Future Market Insights

Follow this link:
Automated Cell Culture Systems Market to Record Strong Growth due to High Demand for Advanced Treatment of Chronic Conditions, Future Market Insights...

CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research – PRNewswire

LANCASTER, Calif., Aug. 3, 2020 /PRNewswire/ -- R. Rex Parris, President and Chairman of the Board of biotech company CarthroniX, announced a donation of $50,000 to Denis Evseenko, MD, Ph.D. of the Keck School of Medicine of USC to support continued research in the field longevity.

Dr. Evseenko was recently awarded a $1.69 million research project grant from the National Institutes of Health to address how to slow arthritis in aging joints. He has helped develop breakthroughs in molecular studies that identified and characterized the unique cell populations that form the superficial human joint cartilage zone.

Dr. Evseenko is one of the world's leading medical researchers of arthritis and how gene activity drives cartilage development. "The CDC reports that 23% of all adults, or 54 million people, have some form of arthritis and are limited in their activities due to severe joint pain," said Mr. Parris. "Dr. Evseenko's work will help tens of millions of people in this country and many more worldwide, living with arthritis's daily struggle. Now there is evidence that it will also extend the quality of life and longevity."

CarthroniX is comprised of scientists and surgeons with expertise in regenerative medicine and stem cell research. Their research is focused on creating novel small molecules to stimulate the regrowth of healthy cartilage. Dr. Evseenko's work fits seamlessly with CarthroniX's goals of extending the quality of life for millions of people. Osteoarthritis is one component of the aging process as cartilage degenerates over time, especially after injury and wear and tear.

Recently it was discovered that some of the small molecules studied to treat arthritis also reverse the aging of human cells in vitro. This gift will enable Dr. Evseenko's lab to advance to the next stage of research. The CX-1 small molecule will hopefully slow the aging of mice. If this is confirmed, CarthroniX will seek FDA approval of human trials to investigate CX-1's effect on human longevity and regeneration of vital organs. "This gift will help us explore some fundamental and transformative questions related to life span extension," said Dr. Evseenko.

CarthroniX novel technologies are proven to preserve, repair, and regenerate cartilage in joints and suppress inflammation in large animals. CarthroniX is developing two types of drugs: one that is both regenerative and anti-inflammatory, and a second that is solely anti-inflammatory.

ABOUT CarthroniX

CarthroniX is developing novel small molecules to stimulate the growth and regeneration of articular cartilage in joints. CarthroniX patented, first-in-class small molecule CX-1 activates an established regenerative pathway; they demonstrated this results in cartilage proliferation, cellular migration, and deposition of cartilaginous matrix.

Media Contact: Joe Marchelewski, [emailprotected]

SOURCE PARRIS Law Firm

Originally posted here:
CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire

UPDATE – Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of…

August 03, 2020 15:36 ET | Source: Cytovia Therapeutics

NEW YORK and MONROVIA, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing natural killer (NK) immunotherapies for cancer, today announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy. Cytovia will conduct and finance all future development and will apply the EGFR Dual-targeting CAR to its iPSC CAR NK technology. CytoImmune will receive an upfront equity grant in Cytovia, future development milestones, and royalties.

Dr. Daniel Teper, Chairman and CEO of Cytovia added: We are honored to collaborate with Dr. Caligiuri, a pioneer in translating biological research on NK cells into impactful therapeutics. He has published solid data with intracranial injection of EGFR CAR NK cells to support their clinical development in glioblastoma. Additionally, EGFR is a clinically validated target which will allow us to expand the use of NK cellular therapy in multiple solid tumors.

Pre-clinical proof of concept data with intracranial administration of the EGFR Dual-targeting CAR-NK cells for the treatment of glioblastoma has been published in Nature Scientific Reports. The EGFR Dual-targeting CAR targets glioblastoma cells expressing EGFR wild-type and/or the mutant EGFR vIII. A single intracranial injection of EGFR CAR NK cells reduced the growth of glioblastoma and showed a statistically significant improvement in survival in animal models. The intracranial injection of the EGFR CAR NK cells remained localized in the brain without entering the systemic circulation or infiltrating extracranial organs or tissues, thus limiting toxicity.

Michael A. Caligiuri, MD, the scientific founder of CytoImmune, has been invited and is planning to join the Cytovia Scientific Advisory Board. Dr Caligiuri is the Deana and Steve Campbell Physician in Chief Distinguished Chair and President of the City of Hope National Medical Center in Duarte, CA. Dr. Caligiuri is a world-renowned physician, scientist, builder, innovator, leader and visionary. He was elected a Member of the National Academy of Medicine for his work on NK cell biology and its clinical applications. He is a past President of the American Association for Cancer Research (AACR).

Dr Caligiuri commented: CAR NK cell therapy has the potential to transform cancer outcomes. We are excited to partner with Cytovia to rapidly bring EGFR Dual-targeting CAR NK cells, a next generation therapy, to patients with the ultimate goal of curing glioblastoma. Cytovias off-the-shelf iPSC CAR NK cell technology should increase the access to precision immunotherapy for many cancer patients.

ABOUT CAR NK CELL THERAPYChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent developments with iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access of cell therapy for many patients.

ABOUT GLIOBLASTOMAGlioblastoma affects 290,000 new patients every year worldwide. Chemotherapy and radiotherapy lack specificity and provide limited efficacy along with high toxicity. The median overall survival from the time of diagnosis is only 14.6 months. Systemic and particularly intracranial or intratumoral immunotherapy, which can target localized and infiltrating cells, has shown initial promise in early clinical trials.

ABOUT CYTOVIA THERAPEUTICS, INC Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF) and the Hebrew University of Jerusalem. Learn more atwww.cytoviatx.com

ABOUT CYTOIMMUNE THERAPEUTICS CytoImmune Therapeutics (CytoImmune) is biotechnology company focused on the application of proprietary chimeric antigen receptors (CAR) for use in both off-the-shelf human natural killer (NK) cells and autologous cytotoxic effector T cells in the treatment of liquid and solid tumors. Our CoalesceNT platform harnesses the power of both a specific CAR and a different secretory bispecific antibody in a single construct to coordinate an immune response with CAR NK cells, cytolytic effector T cells, NK-T cells and g/d T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic response that reflects both innate and adaptive immunity in an effort to reduce tumor evasion and the incidence of cancer recurrence.

Learn more at http://www.cytoimmune.com

Contact for media enquiries Sophie Badr Vice President, Corporate Affairs Sophie.badre@cytoviatx.com 1(929) 317 1565

Will Rossellini President will@cytoimmune.com 1(469) 222 2350

Read the rest here:
UPDATE - Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics' First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of...

FDA-approved treatment puts rare cancer with skin manifestations on the map – Dermatology Times

A small group of scientists and clinicians are trying to build awareness of this cancer, and how to diagnose and treat it. While this rare and aggressive hematologic malignancy hasnt had a standardized therapeutic approach in the past, that is also changing. The FDA approved tagraxofusp (Elzonris, Stemline) in 2019 as the first medication indicated to treat BPDCN, according to a drug review published June 24, 2020 in the journal Expert Review of Anticancer Therapy.1

Progress aside, theres still a long way to go in creating awareness among dermatologists, primary care physicians, emergency department providers and pediatricians all of whom are most likely to encounter people with possible BPDCN, says Naveen Pemmaraju,M.D., associate professor in the department of leukemia at The University of Texas MD Anderson Cancer Center. Dr. Pemmaraju is senior author on the recent Expert Review of Anticancer Therapy paper, and he led the pivotal study published in April 2019 in the New England Journal of Medicine that led to the FDAs approval of tagraxofusp for the treatment of BPDCN.2

Having the clinical trial is great, but now that the drug is commercially available there was a call for what are the practical considerations for Tagraxofusp in BPDCN? Dr. Pemmaraju says. Thats why we wrote this paper.

Dermatologists, take noteDr. Pemmaraju points to three stand-out practical considerations for providers.

One is that most people in medicine have yet to even hear about the disease, he says. When people on the frontlines see skin lesions, the only way theyre going to know whether its BPDCN is with a biopsy. Tissue is the issue, as they say. If something looks irregular, abnormal and if its clinically indicated to do a biopsy, do a biopsy. A lot of these patients get mistaken for other diseases, infections, other cancers. So, I think the biopsy is important.

The need for expert review goes along with the first practical consideration.

CD123 (interleukin-3 receptor alpha unit) is overexpressed in 100% of BPDCN patients. But thats not the only way to differentiate this cancer on biopsy. CD123, CD4, CD56 as the golden triad of BPDCN, according to Dr. Pemmaraju.

Now we know there are other markers, TCL1, TCF 4, CD303 and others. When you put together these three to six markers, it helps you distinguish BPDCN, which is extraordinarily rare compared to the more common cancers like acute myeloid leukemia (AML), cutis, cutaneous t-cell lymphoma. Obviously, this differentiates completely from skin infections and all these other noncancer entities, Dr. Pemmaraju says.

The second practical consideration is that, although rare diseases commonly have limited-to-no treatment options, a therapy for BPDCN exists and more are being investigated. Studies suggest that BPDCN incidence is as low as 0.44% of all hematologic cancers and 0.7% of cutaneous lymphomas, according to the paper. Despite the low numbers, BPDCN treatment is available with tagraxofusp. Researchers are also conducting multiple clinical trials for BPDCN drugs in development, including the B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax, and a chimeric antigen receptor (CAR) T-cell therapy.

The third consideration: The significance of dermatologists and dermatopathologists roles in BPDCN diagnosis.

As we educate our fellow hematologists/oncologists, we must continue to educate dermatologists, many of whom are going to see this disease for the very first time in the clinic before anybody else. I believe BPDCN will soon appear on dermatology and derm-path board exams, Dr. Pemmaraju says.

BPDCN skin lesions usually present as dark and purplish and can be maculopapular.

I would say clinically there is a somewhat distinct look, although I would add the caveat that these lesions act heterogeneously, he says.

Focusing on TagraxofuspResearchers reported that tagraxofusp, aCD123-directed cytotox, demonstrated efficacy in BPDCN patients along with an overall manageable safety profile, according to the NEJM study.

A historically deadly disease, BPDCNs median overall survival after chemotherapy had been 8 to 14 months, according to Dr. Pemmaraju. Hematopoietic stem cell transplant might prolong survival in patients healthy enough to have the stem cell transplant.

Among the 29 previously untreated patients, the survival rates of 59% at 18 months and 52% at 24 months rates that were influenced by the number of patients who went into remission after tagraxofusp therapy and could thus undergo hematopoietic stem-cell transplantation represent an improvement over rates in historically published data. We also observed a 67% overall response rate among previously treated patients. Notably, we report a meaningful survival with tagraxofusp among patients with relapsed or refractory disease (median overall survival, 8.5 months), Dr. Pemmaraju and colleagues report in the NEJM.

Interestingly, patients skin lesions went away rapidly in the vast majority of people treated with tagraxofusp, according to Dr. Pemmaraju.

Capillary leak syndrome emerged as the most drug-associated serious adverse, manifested by edema, tachycardia, hypoalbuminemia and hypotension.

There also is the issue of drug resistance. Researchers have found, in vivo, that resistance to tagraxofusp in cell lines is associated with decreased DPH1 expression and azacitadine might reverse tagraxofusp resistance.

More research is needed to study how combining tagraxofusp with other targeted therapies may improve outcomes. Research also is needed to study tagraxofusp use in pediatric patients. The FDAs approval is for tagraxofusp is as first-line therapy for BPDCN for adults and children ages 2 years and older. But only a small number of pediatric patients have been treated so far, the authors report.

DisclosureMD Anderson funded the study. Dr. Pemmaraju has received research funding/clinical trials support from Affymetrix, SagerStrong Foundation, Novaris, Stemline, Samus, AbbVie, Cellectis, Daiichi Sankyo, and Plexxikon.

References

1. Lee SS, Mccue D, Pemmaraju N. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Rev Anticancer Ther. 2020;:1-8.

2. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380(17):1628-1637.

Read more:
FDA-approved treatment puts rare cancer with skin manifestations on the map - Dermatology Times

Stem Cell Assay Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications – Research Newspaper

The Stem Cell Assay Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report provides an overall analysis of the market based on types, applications, regions, and for the forecast period from 2020 to 2026. It also offers investment opportunities and probable threats in the market based on an intelligent analysis.

This report focuses on the Global Stem Cell Assay Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=50697

Key List Market Participants in the Market: GE Healthcare Promega Corporation Thermo Fisher Scientific Merck KGaA Cell Biolabs Hemogenix

By Types: Viability Purification Identification

By Applications: Regenerative Medicine Clinical Research

Scope of the Stem Cell Assay Market Report:

Fill the Pre-order Inquiry Form for the Report @https://dataintelo.com/enquiry-before-buying/?reportId=50697

By Regions: North America (The USA, Canada, and Mexico) Europe (Germany, France, the UK, and Rest of Europe) Asia Pacific (China, Japan, India, and Rest of Asia Pacific) Latin America (Brazil and Rest of Latin America.) Middle East &Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa).

Report Answers Following Questions:

To Purchase This Report, Visit https://dataintelo.com/checkout/?reportId=50697

Stem Cell Assay Market Historic Data (2015-2019):

Stem Cell Assay Market Forecast (2020-2026):

To Get this Report at an Incredible Discounts, Visit @ https://dataintelo.com/ask-for-discount/?reportId=50697

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, United States. Phone No: USA: +1 909 545 6473 | IND: +91-7000061386 Email: [emailprotected] Website: https://dataintelo.com

View original post here:
Stem Cell Assay Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - Research Newspaper

More on the language of immunity – Cosmos

This continues the process from last week (the I essay) of introducing terms that will be encountered as we engage with the complexities of immunity. Ive bolded a few words and phrases that, while some may be commonplace, will be used in an unfamiliar context. Repertoire is in that category.

Repertoire is mainly owned by the entertainment and performance cultures. The repertoires of: an opera singer or solo instrumentalist; amazing strokes from a top tennis player; tricky moves by a spin bowler; and the playlist that defines the repertoires of both actors and a theatrical company like Bell Shakespeare or the fictional Good Companions in JB Priestleys novel. What were discussing here is a diversity of selected repertoires, with that selection being made first by the performers on the basis of their specific abilities and interests, then by those who care to engage by listening, buying tickets and attending an event as part of their target audience. The audience for, say, the latest Opera Australia production of Don Giovanni at Sydney Opera House will, though there may be some crossover, be largely different from that enjoying live music at a Kings Cross night club.

Immunologists use repertoire in discussing the extraordinary diversity of the adaptive immune system (See Immuno and the Red and the white essays) that has evolved to limit the damage caused by pathogens as different as measles virus and malaria. When it comes to any individual infection, what we are talking about is, in fact, three quite distinct repertoires that incorporate a diversity of highly specific recognition molecules, or receptors, expressed on three very distinct categories of immune white blood cells (WBCs) that do very different jobs in protecting us. Each cell, or lymphocyte (the terms are interchangeable here), within these populations of immune performers expresses only one highly specific receptor that, with its feet anchored firmly in the outer membrane of the cell, is made up of two protein chains. At the outer tip of these molecules, we find individually unique but enormously varied structural motifs (styles?) that bind to one or other target induced by the infectious process, in this case by SARS-CoV-2.

Taking the human performer analogy, it is these targets (we call them antigens in immunology) that are the audience selecting a high-performance repertoire from the enormous pool of possible candidates that live within each and every one of us, just as the nine billion or so human beings on our planet are the precursor pool for the top musicians and sports people selected by target audiences. Fans pay money to see them because they have great regard, or affinity for what they do. The central principle of specific immunity is that high affinity binding of an individual cell surface receptor to a particular target antigen leads to its incorporation in a selected response repertoire.

The three categories of immune lymphocytes that concern us here are the B cells, the CD4+ helper T cells and the CD8+ killer T cells. The B refers to a weird organ in birds called the Bursa of Fabricius where nave, or precursor, B cells first develop and start to express their surface receptors, the B cell receptors (BCRs). Mammals like us dont have that bursa (which has nothing to do with bursitis,) but we think that the same type of process goes on in our bone marrow (BM).

The T refers to the thymus, the organ in the neck that is large in children and gets smaller (involutes) as we age. BM stem cells travel to the thymus via the blood, where they multiply, differentiate and express the T cell receptors (TCRs) that direct the attention of the CD4+ T helpers and CD8+ T killers. After exiting the thymus into the blood, these nave T cell pools provide the narrow, antigen-selected repertoires that coalesce after infection or vaccination.

The CD of CD4 and CD8 is short for cluster of differentiation and is just part of a classification scheme for molecules on the surface of immune cells. Currently, there are 371 members in this molecular club some of which are differentially expressed on the surface of antigen-selected immune T cells (and B cells) as they multiply, then go down different functional pathways. These CD activation markers allow us to characterise distinct CD4+ and CD8+ T cell subsets.

The BCRs on naive B cells are an early form of the immunoglobulin (Ig), or antibody molecules that we met last week. By the time the Igs are being secreted by the B cell descendants, the large protein factory plasma cells, the BCRs will have been refined and changed by a process called affinity maturation that is unique for the B cell/plasma cell lineage and does not happen for the T cells. More of that later.

The CD4+ T helpers are, if you use the performer analogy, the agents and promotors of immunity. The CD8+ T killers are the assassins, the killers within that sounds a bit dangerous, but they are very important. Enough for now!

This article is the latest in theSetting it Straightseries written by Laureate ProfessorPeter Dohertyfrom Australias University of Melbourne and Doherty Institute to explain aspects of the evolving COVID-19 pandemic. You can read them allhere.

See the article here:
More on the language of immunity - Cosmos